The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
 
Yoshiaki Nagatani
No Relationships to Disclose
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Lilly Japan; Merck Serono; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Adlai Nortye; Ono Pharmaceutical; Shift Zero
Research Funding - Adlai Nortye (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst)
 
Tomoko Yamazaki
Speakers' Bureau - Merck; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck; MSD (Inst); Ono Pharmaceutical (Inst)
 
Yukinori Asada
No Relationships to Disclose
 
Masaaki Higashino
No Relationships to Disclose
 
Masahiro Goto
Honoraria - DAIICHI SANKYO COMPANY,LIMITED; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Sumitomo Dainippon Pharma Co., Ltd.; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Chugai Pharma; Nippon Kayaku; Taiho Pharmaceutical
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Ichiro Ota
No Relationships to Disclose
 
Hirokazu Uemura
No Relationships to Disclose
 
Katsunari Yane
No Relationships to Disclose
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Takuma Onoe
No Relationships to Disclose
 
Shigemichi Iwae
Consulting or Advisory Role - Merck (Inst)
Speakers' Bureau - Bristol-Myers Squibb Japan; Merck; MSD; Ono Pharmaceutical
Research Funding - Ascent Development Services (Inst); GlaxoSmithKline (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Shigeru Hirano
No Relationships to Disclose
 
Yoshinori Imamura
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD
 
Shiro Kimbara
No Relationships to Disclose
 
Taku Nose
No Relationships to Disclose
 
Taiji Koyama
No Relationships to Disclose
 
Yohei Funakoshi
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; Nihon Servier; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mitsubishi Tanabe Pharma (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)